NCT04975204 - A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

August 31, 2024

Conditions

Advanced Malignant Tumor

Interventions

DRUG

TQB3909 Tablets

TQB3909 is an inhibitor targeting BCL-2 protein

Trial Locations (2)

RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

RECRUITING

Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin